Cinven, a private equity firm, has announced its acquisition of Amdipharm for £367 million. Amdipharm is a family-owned niche pharmaceutical company, and this acquisition is part of Cinven's strategy to expand its presence in the generic drugs market.

The plan involves merging Amdipharm with Mercury Pharma, which Cinven acquired earlier this year for £465 million. This merger aims to create a significantly larger entity in the generic pharmaceuticals sector. Supraj Rajagopalan, a deal partner at Cinven, expressed ambitions to further expand the business by acquiring additional products from larger pharmaceutical companies looking to streamline their portfolios.

This acquisition marks Cinven's 14th investment in the healthcare sector, underscoring the firm's commitment to growing its footprint in this industry.